Clinical trial
Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00131469 · Oregon Health and Science University, Other · Completed
Key facts
| NCT number | NCT00131469 |
|---|---|
| Title | Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta |
| Official title | A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI) |
| Acronym | OI |
| Lead sponsor | Oregon Health and Science University, Other |
| Collaborators | Eli Lilly and Company Industry Osteogenesis Imperfecta Foundation National Institutes of Health (NIH) NIH National Center for Research Resources (NCRR) |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteogenesis Imperfecta |
| Intervention type | Drug |
| Interventions | Teriparatide (FORTEO), Placebos |
| Enrollment | 79 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Aug 18, 2005 |
| Last update posted | Apr 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: